Literature DB >> 28439138

Bezlotoxumab.

Danial E Baker.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The March 2017 monograph topics are crisaborole, insulin degludec/liraglutide, inclusion glargine/lixisenatide, nusimersen, and rucaparib. The MUE is on insulin GLP-1 combo.

Entities:  

Year:  2017        PMID： 28439138      PMCID： PMC5396991          DOI： 10.1310/hpj5203-229

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  15 in total

1.  Clostridium difficile--beyond antibiotics.

Authors:  Lorraine Kyne
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

Review 2.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

Review 3.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

4.  Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.

Authors:  Lorraine D Hernandez; Fred Racine; Li Xiao; Edward DiNunzio; Nichelle Hairston; Payal R Sheth; Nicholas J Murgolo; Alex G Therien
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

5.  Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.

Authors:  Z Zhang; X Chen; L D Hernandez; P Lipari; A Flattery; S-C Chen; S Kramer; J D Polishook; F Racine; H Cape; C P Kelly; A G Therien
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

Review 6.  Breakthroughs in the treatment and prevention of Clostridium difficile infection.

Authors:  Larry K Kociolek; Dale N Gerding
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-10       Impact factor: 46.802

7.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

8.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

9.  Risk factors for Clostridium difficile infection.

Authors:  G E Bignardi
Journal:  J Hosp Infect       Date:  1998-09       Impact factor: 3.926

Review 10.  Clostridium difficile infection: a review of current and emerging therapies.

Authors:  Andrew Ofosu
Journal:  Ann Gastroenterol       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.